StreetInsider.com News Articles

EyePoint Inc. (EYPT) PT Lowered to $27 at H.C. Wainwright

Thu, 06 Aug 2026 06:55:14 -0400

H.C. Wainwright analyst Yi Chen lowered the price target on EyePoint Inc. (NASDAQ: EYPT) to $27.00 (from $30.00) while maintaining a Buy rating.

Form S-8 EyePoint, Inc.

Wed, 05 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260805/26874718.html

Form S-8 EyePoint, Inc.

Wed, 05 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260805/26874718.html

Form 10-Q EyePoint, Inc. For: Jun 30

Wed, 05 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260805/26874015.html

Form 10-Q EyePoint, Inc. For: Jun 30

Wed, 05 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260805/26874015.html

Form 8-K EyePoint, Inc. For: Aug 05

Wed, 05 Aug 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260805/26870147.html

Form 8-K EyePoint, Inc. For: Aug 05

Wed, 05 Aug 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260805/26870147.html

EyePoint Pharmaceuticals (EYPT) Misses Q2 EPS by 15c

Wed, 05 Aug 2026 07:05:29 -0400

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q2 EPS of ($1.09), $0.15 worse than the analyst estimate of ($0.94). Revenue for the quarter came in at $507 thousand versus the consensus estimate of $383 thousand.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

Wed, 05 Aug 2026 07:00:00 -0400

– Topline data from LUGANO pivotal Phase 3 wet AMD clinical trial expected in August 2026 ––

– Topline data from LUCIA pivotal Phase 3 wet AMD clinical trial anticipated in Q4 2026 ––

– Pivotal Phase 3 DME clinical trials, COMO and CAPRI, fully enrolled over 480 patients in 5 months; topline data expected in Q4 2027 ––

– $180 million of cash and investments as of June 30, 2026, with runway into Q4 2027 ––

WATERTOWN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT),

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

Wed, 05 Aug 2026 07:00:00 -0400

– Topline data from LUGANO pivotal Phase 3 wet AMD clinical trial expected in August 2026 ––

– Topline data from LUCIA pivotal Phase 3 wet AMD clinical trial anticipated in Q4 2026 ––

– Pivotal Phase 3 DME clinical trials, COMO and CAPRI, fully enrolled over 480 patients in 5 months; topline data expected in Q4 2027 ––

– $180 million of cash and investments as of June 30, 2026, with runway into Q4 2027 ––

WATERTOWN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT),

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

Wed, 05 Aug 2026 07:00:00 -0400

– Topline data from LUGANO pivotal Phase 3 wet AMD clinical trial expected in August 2026 ––

– Topline data from LUCIA pivotal Phase 3 wet AMD clinical trial anticipated in Q4 2026 ––

– Pivotal Phase 3 DME clinical trials, COMO and CAPRI, fully enrolled over 480 patients in 5 months; topline data expected in Q4 2027 ––

– $180 million of cash and investments as of June 30, 2026, with runway into Q4 2027 ––

WATERTOWN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT),

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

Wed, 05 Aug 2026 07:00:00 -0400

– Topline data from LUGANO pivotal Phase 3 wet AMD clinical trial expected in August 2026 ––

– Topline data from LUCIA pivotal Phase 3 wet AMD clinical trial anticipated in Q4 2026 ––

– Pivotal Phase 3 DME clinical trials, COMO and CAPRI, fully enrolled over 480 patients in 5 months; topline data expected in Q4 2027 ––

– $180 million of cash and investments as of June 30, 2026, with runway into Q4 2027 ––

WATERTOWN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT),

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

Wed, 05 Aug 2026 07:00:00 -0400

– Topline data from LUGANO pivotal Phase 3 wet AMD clinical trial expected in August 2026 ––

– Topline data from LUCIA pivotal Phase 3 wet AMD clinical trial anticipated in Q4 2026 ––

– Pivotal Phase 3 DME clinical trials, COMO and CAPRI, fully enrolled over 480 patients in 5 months; topline data expected in Q4 2027 ––

– $180 million of cash and investments as of June 30, 2026, with runway into Q4 2027 ––

WATERTOWN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT),

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

Wed, 05 Aug 2026 07:00:00 -0400

– Topline data from LUGANO pivotal Phase 3 wet AMD clinical trial expected in August 2026 ––

– Topline data from LUCIA pivotal Phase 3 wet AMD clinical trial anticipated in Q4 2026 ––

– Pivotal Phase 3 DME clinical trials, COMO and CAPRI, fully enrolled over 480 patients in 5 months; topline data expected in Q4 2027 ––

– $180 million of cash and investments as of June 30, 2026, with runway into Q4 2027 ––

WATERTOWN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT),

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

Wed, 05 Aug 2026 07:00:00 -0400

– Topline data from LUGANO pivotal Phase 3 wet AMD clinical trial expected in August 2026 ––

– Topline data from LUCIA pivotal Phase 3 wet AMD clinical trial anticipated in Q4 2026 ––

– Pivotal Phase 3 DME clinical trials, COMO and CAPRI, fully enrolled over 480 patients in 5 months; topline data expected in Q4 2027 ––

– $180 million of cash and investments as of June 30, 2026, with runway into Q4 2027 ––

WATERTOWN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT),

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

Wed, 05 Aug 2026 07:00:00 -0400

– Topline data from LUGANO pivotal Phase 3 wet AMD clinical trial expected in August 2026 ––

– Topline data from LUCIA pivotal Phase 3 wet AMD clinical trial anticipated in Q4 2026 ––

– Pivotal Phase 3 DME clinical trials, COMO and CAPRI, fully enrolled over 480 patients in 5 months; topline data expected in Q4 2027 ––

– $180 million of cash and investments as of June 30, 2026, with runway into Q4 2027 ––

WATERTOWN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT),

Citi opens 90-day upside catalyst call on EyePoint

Wed, 05 Aug 2026 06:31:20 -0400

Citi analyst Yigal Nochomovitz reiterated a Buy rating and $35.00 price target on EyePoint Inc. (NASDAQ: EYPT), according to a press release statement.

The analyst cited expectations for Phase 3 clinical trial data for DURAVYU in wet age-related macular degeneration (wAMD), with topline results from the LUGANO trial expected in mid-to-late August, followed by the LUCIA trial approximately eight weeks later.

Nochomovitz noted that masked safety data has continued to track in line with DURAVYU's prior four clinical trials, with a discontinuation rate of approximately 6%, which is below the roughly 10% annual average for wAMD trials. The analyst also pointed to

Form SCHEDULE 13G EyePoint, Inc. Filed by: VANGUARD CAPITAL MANAGEMENT LLC

Fri, 31 Jul 2026 10:19:00 -0400

si-local-file:///var/storage/secattach/20260731/26848192.html

Form SCHEDULE 13G EyePoint, Inc. Filed by: VANGUARD CAPITAL MANAGEMENT LLC

Fri, 31 Jul 2026 10:19:00 -0400

si-local-file:///var/storage/secattach/20260731/26848192.html

Form 8-K EyePoint, Inc. For: Jul 30

Thu, 30 Jul 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260730/26838534.html

Form 8-K EyePoint, Inc. For: Jul 30

Thu, 30 Jul 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260730/26838534.html

EyePoint completes enrollment in two phase 3 DME drug trials

Thu, 30 Jul 2026 07:01:05 -0400

EyePoint, Inc. (NASDAQ: EYPT) announced it has completed enrollment in two global Phase 3 clinical trials — COMO and CAPRI — evaluating its investigational treatment DURAVYU (vorolanib intravitreal insert) for diabetic macular edema (DME).

More than 480 patients were enrolled across both trials in five months, which the company said was ahead of schedule. Topline data from both trials are anticipated in the fourth quarter of 2027.

COMO and CAPRI are randomized, double-masked, non-inferiority trials comparing DURAVYU 2.7mg, dosed every six months, against on-label 2mg aflibercept. The trials include both treatment-naïve and previously treated patients. The primary endpoint is a non-inferior change

EyePoint completes enrollment in two phase 3 DME drug trials

Thu, 30 Jul 2026 07:01:05 -0400

More than 480 patients were enrolled across both trials in five months, which the company said was ahead of schedule. Topline data from both trials are anticipated in the fourth quarter of 2027.

EyePoint completes enrollment in two phase 3 DME drug trials

Thu, 30 Jul 2026 07:01:05 -0400

More than 480 patients were enrolled across both trials in five months, which the company said was ahead of schedule. Topline data from both trials are anticipated in the fourth quarter of 2027.

EyePoint completes enrollment in two phase 3 DME drug trials

Thu, 30 Jul 2026 07:01:05 -0400

More than 480 patients were enrolled across both trials in five months, which the company said was ahead of schedule. Topline data from both trials are anticipated in the fourth quarter of 2027.